Four Hours — What Medical Education Didn't Cover About Headache
Medical education allocates four hours to headache disorders. This card covers the minimum pathophysiology that changes how you document, prescribe, and file prior authorizations — science with direct operational consequences.
PA impact: This card directly affects prior authorization outcomes. Documentation language from this card can be used in PA letters and appeals.
Opening
Medical education allocates approximately four hours to headache disorders across the entire curriculum. Four hours — for a condition that is the second leading cause of disability worldwide, affects one in seven adults, generates more than a million emergency department visits per year in the United States, and will be among the most common diagnoses in any primary care panel. Most of what's clinically useful for migraine management in primary care was learned on the job, absorbed from pharmaceutical representatives, or never learned at all.
This card is a compressed reference for what those four hours didn't cover. It is not a neurology lecture. It's the minimum pathophysiology that changes how you document, prescribe, and file prior authorizations — science with direct operational consequences.
The vascular theory is dead — stop using "vascular headache"
Migraine was taught as a vascular disorder: vasoconstriction causing aura, vasodilation causing pain. That model was the dominant framework through the 1990s and is still embedded in clinical language, older reference materials, and many clinicians' mental models.
It doesn't hold. Migraine is a disorder of sensory processing involving cortical spreading depression (the aura mechanism), trigeminal nerve activation, and central sensitization. The vascular changes are consequences of the neurological event, not causes.
Why this matters for your practice: "Vascular headache" in a clinical note signals outdated understanding to a specialist reviewer. More practically: the vascular model implies that non-vascular patients don't have "real" migraines, and that vasoactive treatments (triptans) are the only mechanism-appropriate therapy. Both implications are wrong. CGRP mAbs and gepants work through non-vascular mechanisms and are first-line for patients who can't use vasoconstrictors.
CGRP is the mechanism, not just a drug target
Calcitonin gene-related peptide is released during migraine attacks and sensitizes trigeminal pain pathways. CGRP mAbs don't mask symptoms — they interrupt the pathological cascade. This distinction matters when patients (or clinicians) question whether preventive medication is "just covering up the problem."
PA documentation consequence: "Mechanism-specific preventive therapy targeting the CGRP pathway" is stronger language than "another preventive to try." It communicates that the clinician understands why this class exists and why it's different from repurposed beta-blockers and anticonvulsants.
Why CGRPs are different from repurposed preventives
Beta-blockers, anticonvulsants, and antidepressants work for migraine through poorly understood, off-target mechanisms. They carry side effect profiles from their primary indications — cognitive impairment (topiramate), weight gain (valproate, amitriptyline), fatigue and bradycardia (propranolol), teratogenicity (topiramate, valproate). These are medications borrowed from other conditions that happen to reduce migraine frequency for reasons we don't fully understand.
CGRP mAbs were the first preventive medications designed specifically for migraine, with migraine-specific mechanisms and correspondingly cleaner side effect profiles. This explains both the clinical enthusiasm and the cost differential.
Chronification is biological, not behavioral
Repeated migraine attacks physically change brain structure and function — gray matter volume changes, altered pain processing networks, progressive central sensitization. A patient who progresses from episodic to chronic migraine hasn't failed to manage their condition. Their condition has progressed. This is disease biology, not patient behavior.
PA documentation consequence: "Disease progression from episodic to chronic migraine despite treatment" is substantially stronger than "worsening headaches" or "increased frequency." It frames escalation to CGRP therapy or Botox as a response to biological disease progression, not a convenience upgrade.
The library in context
Primary care IS the headache workforce. There are approximately 7,200 headache specialists serving 39 million migraine patients — one specialist per 47,000 people. The realistic model is primary care managing the vast majority of migraine patients with specialist-level decision support tools. That's what this library is.
Every card in this library implicitly compensates for those four hours. The NDPH card (Card 13) exists because G44.52 coding consequences weren't covered. The MOH card (Card 2) exists because the medication overuse threshold isn't intuitive. The aura/contraception card (Card 5) exists because the stroke risk multiplication wasn't emphasized. The acute treatment ladder (Card 7) exists because step therapy mechanics aren't taught in any medical school curriculum.
Ready to run a PA?
The PA Engine applies this guidance automatically — paste a clinical note and get a complete, payer-specific PA letter in under a minute. Free, no account required.
Run a PA — free →Citations: Goadsby PJ, Holland PR, et al. Physiological Reviews 2017;97(2):553-622 | Charles A. Lancet Neurology 2018;17(2):174-182 | Ashina M, et al. NEJM 2020;383(19):1866-1876 | Gelinas B, et al. Headache 2020;60(8):1543-1552 [four hours figure] | Headache Vault National Provider Analysis (CMS Medicare Part D, 2024).